HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

2- ethoxy- 3- (4- ((4- (methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acid

structure in first source
Also Known As:
(S)-2-ethoxy-3-(4-((4-(methylsulfonyloxy)phenethyl)oxy)phenyl)propanoic acid; tesaglitazar
Networked: 25 relevant articles (5 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Ohman, K Peter: 4 articles (09/2012 - 12/2006)
2. Skånberg, Inger: 3 articles (01/2012 - 07/2007)
3. Westerberg, Rolf: 3 articles (01/2012 - 07/2007)
4. Berg, Anna-Lena: 3 articles (01/2012 - 07/2007)
5. Blomgren, Bo: 3 articles (01/2012 - 07/2007)
6. Hellmold, Heike: 3 articles (01/2012 - 07/2007)
7. Gause-Nilsson, Ingrid: 3 articles (03/2008 - 09/2007)
8. Tonstad, Serena: 3 articles (03/2008 - 09/2007)
9. Karlsson, Mats O: 2 articles (09/2012 - 06/2008)
10. Hamrén, Bengt: 2 articles (09/2012 - 06/2008)

Related Diseases

1. Insulin Resistance
2. Dyslipidemias (Dyslipidemia)
11/01/2005 - "AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients."
12/01/2006 - "Similar numbers of adverse events occurred in the tesaglitazar < or = 1.0 mg, placebo, and pioglitazone arms, but there was an increasing frequency of discontinuations due to pre-specified hematologic and clinical-chemistry criteria with tesaglitazar doses > or = 1.0 mg. In type 2 diabetic patients, tesaglitazar dose-dependently reduced FPG levels at doses > or = 0.5 mg. Other markers of glycemic control, atherogenic dyslipidemia, and measures associated with insulin resistance were improved at doses > or = 0.5 mg or > or = 1.0 mg. Study limitations included that the majority of patients were white, patients had good glycemic control at baseline, and the increased number of early withdrawals in the tesaglitazar 2.0 mg and 3.0 mg doses limits conclusions about the efficacy of these doses. "
09/01/2007 - "In conclusion, the addition of tesaglitazar to a background of atorvastatin therapy further improved the dyslipidemia associated with insulin resistance."
01/01/2010 - "Tesaglitazar treatment in OZR significantly reduced nonfasting glucose, C-reactive protein levels and improved dyslipidemia. "
09/01/2007 - "This study compared the efficacy of tesaglitazar with that of pioglitazone as adjunctive therapy to atorvastatin in subjects with abdominal obesity and dyslipidemia. "
3. Type 2 Diabetes Mellitus (MODY)
4. Abdominal Obesity
5. Fibrosis (Cirrhosis)

Related Drugs and Biologics

1. pioglitazone (Actos)
2. Glucose (Dextrose)
3. Iothalamic Acid (Iotalamic Acid)
4. atorvastatin (Lipitor)
5. C-Reactive Protein
6. PPAR alpha
7. Insulin (Novolin)
8. Collagen
9. Peroxisome Proliferator-Activated Receptors (PPAR)
10. LDL Receptors (LDL Receptor)